Boyd S, Owens D, Gin T, Bunce K, Sherafat H, Perry D, Hykin P G
Moorfields Eye Hospital, City Road, London EC1V 2PD, UK.
Br J Ophthalmol. 2001 Nov;85(11):1313-5. doi: 10.1136/bjo.85.11.1313.
To determine whether plasma homocysteine, methylene tetrahydrofolate reductase (MTHFR) C677T and factor II G20210A polymorphisms, factor VIII, and vWF are risk factors for central retinal vein occlusion (CRVO).
Prospective comparison of 63 consecutive patients with central retinal vein occlusion and 63 age matched controls. Plasma homocysteine and vWF were estimated by ELISA, the MTFHR and factor II G20210A polymorphisms determined by polymerase chain reaction with restriction enzyme product digestion and factor VIII by one stage automated clotting assay.
Plasma homocysteine (patients: median 12.4 micromol/l, controls: median 11.6 micromol OR = 1.05, p=0.20), factor VIII (patients: median = 115 U/dl, controls: median = 113 U/dl), and vWF (patients: median = 115 U/dl, controls: median = 108 U/dl) were not statistically higher in patients than in controls. Five CRVO patients and seven controls were homozygous for the MTHFR C677T mutation. One control was heterozygous for the factor II G20210A mutation.
This study has not identified new risk factors for CRVO.
确定血浆同型半胱氨酸、亚甲基四氢叶酸还原酶（MTHFR）C677T和凝血因子II G20210A基因多态性、凝血因子VIII及血管性血友病因子（vWF）是否为视网膜中央静脉阻塞（CRVO）的危险因素。
对63例连续性视网膜中央静脉阻塞患者及63例年龄匹配的对照者进行前瞻性比较。采用酶联免疫吸附测定法（ELISA）评估血浆同型半胱氨酸和vWF，通过聚合酶链反应-限制性内切酶产物消化法检测MTHFR和凝血因子II G20210A基因多态性，采用一步自动凝血分析法检测凝血因子VIII。
患者血浆同型半胱氨酸（患者：中位数12.4微摩尔/升，对照者：中位数11.6微摩尔/升，比值比（OR）=1.05，p = 0.20）、凝血因子VIII（患者：中位数 = 115单位/分升，对照者：中位数 = 113单位/分升）和vWF（患者：中位数 = 115单位/分升，对照者：中位数 = 108单位/分升）在统计学上并不高于对照者。5例CRVO患者和7例对照者为MTHFR C677T突变纯合子。1例对照者为凝血因子II G20210A突变杂合子。
本研究未发现CRVO的新危险因素。
